ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AXN Aoxing Pharmaceutical Company New (delisted)

0.1218
0.00 (0.00%)
Pre Market
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aoxing Pharmaceutical Company New (delisted) AMEX:AXN AMEX Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1218 0.00 00:00:00

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aoxing Pharmaceutical Company, Inc.

03/12/2015 3:38pm

PR Newswire (US)


Aoxing Pharmaceutical Company New (delisted) (AMEX:AXN)
Historical Stock Chart


From Feb 2020 to Feb 2025

Click Here for more Aoxing Pharmaceutical Company New (delisted) Charts.

NEW YORK, Dec. 3, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Aoxing Pharmaceutical Company, Inc. ("Aoxing Pharmaceutical" or the "Company") (NYSE -MKT: AXN -News).  Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.

The investigation concerns whether Aoxing Pharmaceutical and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On December 1, 2015, post-market, Aoxing reported the resignation of Wilfred Chow, the Company's Chief Financial Officer, on November 30, 2015.  Following this news, Aoxing Pharmaceutical shares fell $0.07, or 5.11%, to close at $1.30.

If you are aware of any facts relating to this investigation, or purchased shares of Aoxing Pharmaceutical, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-aoxing-pharmaceutical-company-inc-300187633.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Copyright 2015 PR Newswire

1 Year Aoxing Pharmaceutical Company New (delisted) Chart

1 Year Aoxing Pharmaceutical Company New (delisted) Chart

1 Month Aoxing Pharmaceutical Company New (delisted) Chart

1 Month Aoxing Pharmaceutical Company New (delisted) Chart